LAVA Medtech Acquisition Corp.
LVACU
NASDAQ Global Market10.40
USD
- -
- -
LAVA Medtech Acquisition Corp.
LVACU
(NASDAQ Global Market)
Recent
price
10.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- LAVA Medtech Acquisition Corp. (LVACU) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the medtech and healthcare-related industries; it currently conducts no significant operations beyond pursuing such opportunities. Founded in 2021 and headquartered at 303 Wyman Street, Suite 300, Waltham, Massachusetts, the company is a subsidiary of LAVA Medtech Sponsor LP and targets medtech sector assets, primarily in the US and Canada. Its leadership includes CEO Anthony J. Natale, MD, MBA; Chairman Richard Emmitt; President Gerry Brunk; and other executives with medtech experience. The company raised $115 million in gross proceeds through its initial public offering of 11.5 million units at $10.00 per unit in October 2021, with each unit comprising one share of Class A common stock and one-half of a redeemable warrant exercisable at $11.50 per share; units trade on Nasdaq under LVACU, with separate trading of shares (LVAC) and warrants (LVACW) commencing in December 2021. In April 2023, following stockholder approval of a potential extension, the board abandoned further efforts to complete an initial business combination due to adverse market conditions and regulatory uncertainty around SPACs, electing instead to dissolve and liquidate effective April 29, 2023; all outstanding Public Shares were redeemed at approximately $10.42 per share, with warrants expiring worthless and no distributions to the sponsor's Class B shares. Despite the 2023 liquidation announcement, trading data as of late 2025 shows LVACU units priced around $10.40 with a market capitalization of approximately $134 million, alongside recent financial reporting such as second quarter 2025 results indicating total current assets of $60.5 million, suggesting ongoing activity or residual market presence potentially related to post-liquidation share values or platform listings. The company has not announced any new partnerships, acquisitions, funding rounds, product launches, or strategic shifts since the liquidation decision.